Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke
Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the safety and tolerability of Human
Placenta-Derived Cells (PDA001) at 3 different dose levels versus placebo (vehicle control)
administered intravenously in subjects following ischemic stroke. The secondary objective of
the study is to assess the effect of PDA001 on improvement in clinical function following
ischemic stroke.